Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.75 CAD | -2.52% | +22.43% | +24.20% |
Jun. 03 | Kits Eyecare Ltd. Launches Largest Optical Direct Billing Agreement in Canada | CI |
May. 30 | Kits Eyecare Announced TSX Acceptance Of Normal Course Issuer Bid | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 90.31 | 83.85 | 196 | 250 | - | - |
Enterprise Value (EV) 1 | 92.74 | 78.2 | 189.7 | 243.4 | 234.5 | 250 |
P/E ratio | -5.92 x | - | -89.1 x | 795 x | 99.4 x | - |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 1.1 x | 0.91 x | 1.63 x | 1.73 x | 1.49 x | - |
EV / Revenue | 1.13 x | 0.85 x | 1.57 x | 1.68 x | 1.4 x | - |
EV / EBITDA | -11.6 x | -42.8 x | 83.1 x | 50.1 x | 24.5 x | - |
EV / FCF | -4.02 x | 17.7 x | 103 x | 26.7 x | 34.3 x | 26.7 x |
FCF Yield | -24.9% | 5.65% | 0.97% | 3.74% | 2.92% | 3.74% |
Price to Book | 1.65 x | - | - | - | - | - |
Nbr of stocks (in thousands) | 31,141 | 31,287 | 31,411 | 31,450 | - | - |
Reference price 2 | 2.900 | 2.680 | 6.240 | 7.950 | 7.950 | 7.950 |
Announcement Date | 3/9/22 | 3/9/23 | 3/6/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | 75.22 | 82.4 | 91.64 | 120.5 | 144.7 | 167.9 | - |
EBITDA 1 | 3.548 | -8.004 | -1.828 | 2.284 | 4.858 | 9.58 | - |
EBIT 1 | 0.122 | -17.04 | -4.352 | -2.382 | 1.806 | 4.078 | - |
Operating Margin | 0.16% | -20.68% | -4.75% | -1.98% | 1.25% | 2.43% | - |
Earnings before Tax (EBT) 1 | -7.088 | -18.84 | - | - | 0.7 | 4 | - |
Net income 1 | -6.583 | -14.62 | - | -2.215 | 0.5 | 2.9 | - |
Net margin | -8.75% | -17.74% | - | -1.84% | 0.35% | 1.73% | - |
EPS 2 | -0.7200 | -0.4900 | - | -0.0700 | 0.0100 | 0.0800 | - |
Free Cash Flow 1 | 3.957 | -23.09 | 4.419 | 1.842 | 9.1 | 6.846 | 9.364 |
FCF margin | 5.26% | -28.03% | 4.82% | 1.53% | 6.29% | 4.08% | - |
FCF Conversion (EBITDA) | 111.53% | - | - | 80.65% | 187.31% | 71.45% | - |
FCF Conversion (Net income) | - | - | - | - | 1,820% | 236.06% | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/15/21 | 3/9/22 | 3/9/23 | 3/6/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 20.27 | 20.05 | 21.77 | 23.58 | 26.24 | 27.67 | 30.03 | 31.15 | 31.66 | 34.78 | 36.87 | 35.83 | 36.43 | 39.73 | 42.1 |
EBITDA 1 | -1.177 | - | -0.556 | -0.795 | 0.441 | 0.304 | 0.513 | 0.605 | 0.862 | 0.609 | 1.233 | 1.3 | 1.733 | 2.433 | 2.8 |
EBIT 1 | -3.212 | -1.769 | -0.722 | 0.166 | -1.222 | -0.913 | -1.224 | 0.67 | -0.915 | 0.402 | 0.4 | 0.1 | 0.3 | 0.9 | 1.4 |
Operating Margin | -15.85% | -8.82% | -3.32% | 0.7% | -4.66% | -3.3% | -4.08% | 2.15% | -2.89% | 1.16% | 1.08% | 0.28% | 0.82% | 2.27% | 3.33% |
Earnings before Tax (EBT) 1 | -3.612 | - | - | - | - | -1.294 | -1.45 | 0.552 | -0.699 | 0.082 | 0.3 | 0.1 | 0.3 | 0.9 | 1.4 |
Net income 1 | -4.054 | - | - | - | - | -1.02 | -1.184 | 0.48 | -0.491 | 0.064 | 0.2 | 0.318 | 0.2 | 0.6 | 1 |
Net margin | -20% | - | - | - | - | -3.69% | -3.94% | 1.54% | -1.55% | 0.18% | 0.54% | 0.89% | 0.55% | 1.51% | 2.38% |
EPS 2 | -0.1300 | - | - | - | - | -0.0300 | -0.0400 | 0.0100 | -0.0200 | - | 0.0100 | 0.0100 | 0.0150 | 0.0200 | 0.0300 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/9/22 | 5/11/22 | 8/11/22 | 11/9/22 | 3/9/23 | 5/10/23 | 8/9/23 | 11/8/23 | 3/6/24 | 5/8/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | 2.44 | - | - | - | - | - |
Net Cash position 1 | - | - | 5.65 | 6.32 | 6.65 | 15.6 | - |
Leverage (Debt/EBITDA) | - | -0.3042 x | - | - | - | - | - |
Free Cash Flow 1 | 3.96 | -23.1 | 4.42 | 1.84 | 9.1 | 6.85 | 9.36 |
ROE (net income / shareholders' equity) | - | -53.9% | -8.39% | -4.21% | -0.5% | 0.4% | - |
ROA (Net income/ Total Assets) | -12% | -20.1% | -4.93% | -2.44% | -0.3% | 0.3% | - |
Assets 1 | 54.66 | 72.8 | - | 90.75 | -166.7 | 966.7 | - |
Book Value Per Share | -0.0600 | 1.760 | - | - | - | - | - |
Cash Flow per Share 2 | 0.4500 | -0.6500 | 0.1500 | 0.0800 | 0.2800 | 0.2400 | - |
Capex 1 | 0.23 | 3.63 | 0.26 | 0.56 | 0.2 | 0.61 | 0.52 |
Capex / Sales | 0.3% | 4.41% | 0.28% | 0.47% | 0.14% | 0.36% | - |
Announcement Date | 3/15/21 | 3/9/22 | 3/9/23 | 3/6/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.20% | 184M | |
-9.64% | 4.02B | |
+21.40% | 788M | |
-21.81% | 553M | |
-28.59% | 351M | |
+25.45% | 197M | |
-24.12% | 126M | |
+8.72% | 124M | |
+0.33% | 92.65M | |
+15.49% | 79M |
- Stock Market
- Equities
- KITS Stock
- Financials Kits Eyecare Ltd.